Who
John P. Butler
CEO and President
Company insider
Files Form 4 as: CEO and President, Akebia Therapeutics; Director, Zynerba Pharmaceuticals; Director, Keryx Biopharmaceuticals; Director, Relypsa.
In numbers
- Trades disclosed
- 123
- Buys
- 8
- Sells
- 16
- Bought
- $658K
- Sold
- $2.1M
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 14 Nov 2013
- Last trade
- 6 Aug 2026
- Last filed
- 10 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Aug 2026filed 10 Aug 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Code M | $221K350,000 at $0.63 | filing |
| 6 Aug 2026filed 10 Aug 2026 | AKBA Akebia Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —350,000 at $0.00 | filing |
| 6 Aug 2026filed 10 Aug 2026 | AKBA Akebia Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —350,000 at $0.00 | filing |
| 6 Aug 2026filed 10 Aug 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Code M | $221K350,000 at $0.63 | filing |
| 4 Mar 2026filed 5 Mar 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Bought | $87K69,270 at $1.25 | filing |
| 4 Mar 2026filed 5 Mar 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Bought | $87K69,270 at $1.25 | filing |
| 2 Feb 2026filed 4 Feb 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $65K46,660 at $1.39 | filing |
| 2 Feb 2026filed 4 Feb 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $134K96,065 at $1.39 | filing |
| 2 Feb 2026filed 4 Feb 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $160K114,891 at $1.39 | filing |
| 2 Feb 2026filed 4 Feb 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Code A | $247K175,250 at $1.41 | filing |
| 2 Feb 2026filed 4 Feb 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $116K83,689 at $1.39 | filing |
| 2 Feb 2026filed 4 Feb 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $65K46,660 at $1.39 | filing |
| 2 Feb 2026filed 4 Feb 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $134K96,065 at $1.39 | filing |
| 2 Feb 2026filed 4 Feb 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $160K114,891 at $1.39 | filing |
| 2 Feb 2026filed 4 Feb 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Code A | $247K175,250 at $1.41 | filing |
| 2 Feb 2026filed 4 Feb 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $116K83,689 at $1.39 | filing |
| 30 Jan 2026filed 3 Feb 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —743,000 at $0.00 | filing |
| 30 Jan 2026filed 3 Feb 2026 | AKBA Akebia Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —1,115,000 at $0.00 | filing |
| 30 Jan 2026filed 3 Feb 2026 | AKBA Akebia Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —1,115,000 at $0.00 | filing |
| 30 Jan 2026filed 3 Feb 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —743,000 at $0.00 | filing |
News
Analyzing Akebia Therapeutics (NASDAQ:AKBA) and Pharming Group (NASDAQ:PHAR)AKBA · tickerreport.com · 18 Oct 2026
0 headlines in the last 90 days name John P. Butler; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.